Physician profile
Sara D Collins
NPI 1023275229
$60,869.90
in general payments reported to CMS, 2019-2025
37 companies · $43K in 2025
The $43K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $829 · 2021: $8,247 · 2022: $353 · 2023: $484 · 2024: $6,710 · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Food and Beverage: $3,662 · Travel and Lodging: $2,440 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,642.50 |
| Food and Beverage | $3,662.40 |
| Travel and Lodging | $2,440.03 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29,257.02 | 2019-2025 | Repatha, Repatha |
| Ucb, INC. | $7,595.00 | 2021 | |
| Eli Lilly and Company | $7,542.02 | 2024-2025 | |
| Pfizer INC. | $6,347.11 | 2019-2025 | |
| Novo Nordisk INC | $3,819.68 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $1,576.65 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Confirm Rx |
| Novartis Pharmaceuticals Corporation | $1,400.85 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,032.02 | 2023-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $362.01 | 2019-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $227.87 | 2019-2023 | Farxiga |
| Medtronic, INC. | $210.29 | 2024-2025 | Symplicity G3, Linq II |
| Boston Scientific Corporation | $172.76 | 2019-2025 | Watchman Flx, Bodyguardian, Patientcare Link |
| Janssen Pharmaceuticals, INC | $136.18 | 2019-2024 | Xarelto |
| Cardiovascular Systems INC. | $129.27 | 2019 | |
| Edwards Lifesciences Corporation | $118.70 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $117.97 | 2019 | |
| Biotronik INC. | $110.28 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $105.70 | 2020-2025 | Eliquis |
| Astellas Pharma Global Development | $90.90 | 2020 | |
| Esperion Therapeutics, INC. | $71.42 | 2020-2021 | |
| Gilead Sciences, INC. | $51.86 | 2019 | |
| Philips North America LLC | $48.25 | 2020-2024 | (Ck4) Mcot |
| Heartflow, INC. | $45.44 | 2024 | |
| Amarin Pharma, INC. | $37.62 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $34.94 | 2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.94 | 2023 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $32.61 | 2024 | Arcalyst |
| Atricure, INC. | $28.44 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.50 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.44 | 2021 | |
| Impulse Dynamics (USA) INC. | $16.50 | 2022 | |
| Irhythm Technologies, INC. | $15.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.41 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.